HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kratom Reprieve From Scheduling Requested By House Members

This article was originally published in The Rose Sheet

Executive Summary

Members headed by Reps. Mark Pocan, D-WI, and Matt Salmon, R-AZ, say the proposal was made without allowing opportunity for comment by experts, supplement industry stakeholders and consumers.

You may also be interested in...



FDA Turns Kratom's Future In US Dietary Supplement Market Into History

FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."

Kratom Group Wants DEA Records: Health And Wellness Industry News

CRN pans AASLD study linking supplements to rash of liver injuries; ABC goes digital with "Identification of Medicinal Plants"; and AKA says DEA running "shadow campaign" to schedule kratom.

Controversy Brews With 'Inaccurate' Reports Linking Kratom To Deaths

American Kratom Association and independent researchers explain the ingredient's history of safe use in a media briefing. Medical examiners "have tried to pin on kratom" the recent deaths of men in Florida and New York, says trade group Chairman Dave Herman.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel